Precipio Inc (PRPO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Precipio Inc (PRPO) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.00K) by net assets ($13.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Precipio Inc (PRPO) net asset quality to measure how much of total assets are equity-financed.
Precipio Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Precipio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Precipio Inc to evaluate the quality of earnings relative to operating cash generation.
Precipio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precipio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XPLUS SA ZY -01
F:75R
|
0.206x |
|
MUI Properties Bhd
KLSE:3913
|
0.757x |
|
iCRAFT Co. Ltd
KQ:052460
|
0.170x |
|
Unisync Corp
TO:UNI
|
0.082x |
|
Salomon A Angel Ltd
TA:ANGL
|
0.071x |
|
Take Solutions Limited
NSE:TAKE
|
-0.122x |
|
Pantaflix AG
XETRA:PAL
|
1.592x |
|
SMCG Co., Ltd.
KQ:460870
|
-0.045x |
Annual Cash Flow Conversion Efficiency for Precipio Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Precipio Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see PRPO market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.09 Million | $439.00K | 0.036x | +114.72% |
| 2023-12-31 | $14.43 Million | $-3.56 Million | -0.247x | +47.71% |
| 2022-12-31 | $16.37 Million | $-7.72 Million | -0.472x | -76.47% |
| 2021-12-31 | $24.60 Million | $-6.58 Million | -0.267x | +49.08% |
| 2020-12-31 | $14.16 Million | $-7.43 Million | -0.525x | +24.17% |
| 2019-12-31 | $13.21 Million | $-9.14 Million | -0.692x | +37.24% |
| 2018-12-31 | $6.12 Million | $-6.75 Million | -1.103x | -114.76% |
| 2017-12-31 | $13.03 Million | $-6.69 Million | -0.514x | -379.96% |
| 2016-12-31 | $-19.35 Million | $-3.55 Million | 0.183x | -81.00% |
| 2015-12-31 | $-12.82 Million | $-12.38 Million | 0.966x | +146.18% |
| 2014-12-31 | $6.55 Million | $-13.70 Million | -2.091x | -182.46% |
| 2013-12-31 | $11.45 Million | $-8.47 Million | -0.740x | -47.08% |
| 2012-12-31 | $20.27 Million | $-10.20 Million | -0.503x | -2627.50% |
| 2011-12-31 | $11.05 Million | $220.00K | 0.020x | +109.85% |
| 2010-12-31 | $8.50 Million | $-1.72 Million | -0.202x | -286.04% |
| 2009-12-31 | $11.66 Million | $1.27 Million | 0.109x | +447.37% |
| 2008-12-31 | $13.21 Million | $-413.00K | -0.031x | +84.99% |
| 2007-12-31 | $14.10 Million | $-2.94 Million | -0.208x | -175.78% |
| 2006-12-31 | $16.04 Million | $-1.21 Million | -0.076x | +62.69% |
| 2005-12-31 | $17.91 Million | $-3.63 Million | -0.203x | +63.20% |
| 2004-12-31 | $16.54 Million | $-9.10 Million | -0.550x | -87.24% |
| 2003-12-31 | $45.06 Million | $-13.24 Million | -0.294x | -0.77% |
| 2002-12-31 | $61.51 Million | $-17.94 Million | -0.292x | -115.44% |
| 2001-12-31 | $82.10 Million | $-11.12 Million | -0.135x | -110.93% |
| 2000-12-31 | $73.97 Million | $-4.75 Million | -0.064x | -101.54% |
| 1999-12-31 | $-2.10 Million | $-8.74 Million | 4.165x | -- |
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomar… Read more